Vigonvita Life Sciences Co., Ltd. (2630)

Overview

Vigonvita Life Sciences Co., Ltd. is a biopharmaceutical company based in China, primarily engaged in the discovery, development, and commercialization of small molecule drugs. With a specific emphasis on therapeutic areas such as neuropsychiatric disorders, reproductive health, infectious diseases, cardio-cerebrovascular conditions, and oncology, Vigonvita aims to address significant unmet clinical needs through innovative solutions. The company boasts a fully integrated drug innovation system that encompasses various stages of the drug development process, including drug design and discovery, druggability assessment, preclinical and clinical research, pharmaceutical manufacturing, and market launch. Founded in 2013 and headquartered in Suzhou, Vigonvita also maintains manufacturing facilities that comply with Good Manufacturing Practice (GMP) and Environmental Health and Safety (EHS) standards. It operates within China and Uzbekistan, while actively expanding into regions such as North Africa, Central Asia, the Middle East, and Russia. Through a competitive pipeline of products, Vigonvita remains committed to advancing healthcare solutions in the fields it serves.

Products and Services

• MINDVY (VV116)

  MINDVY is an oral nucleoside prodrug that has been approved for the treatment of SARS-CoV-2 infections. Additionally, it is currently under development for other viral infections, specifically respiratory syncytial virus and human metapneumovirus, demonstrating the company's commitment to addressing viral outbreaks and enhancing patient care in infectious diseases.

• ONVITA (TPN171) or Angweida (Simenafil Hydrochloride Tablets)

  ONVITA is a phosphodiesterase 5 inhibitor specifically designed for the treatment of erectile dysfunction and pulmonary arterial hypertension. By targeting these conditions, Vigonvita aims to improve the quality of life for patients affected by such disorders.